ZHUZY yields 4.01% · PFE yields 6.13%● Live data
📍 ZHUZY pulled ahead of the other in Year 1
Combined, ZHUZY + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ZHUZY + PFE for your $10,000?
Zhuzhou CRRC Times Electric Co., Ltd., together with its subsidiaries, engages in the research, development, design, manufacture, and sale of railway transportation equipment products, and provision of relevant services primarily in Mainland China and internationally. The company's products include traction converter systems of rail transit vehicles, railway engineering machinery, and communication signal systems. It also produces propulsion and control systems for trains and electric vehicles, signaling systems, power supply solutions, platform screen doors, rail maintenance vehicles, marine engineering equipment, and component products for various applications. The company's products for rolling stock and railways include EMU, locomotive, and mass transit systems; and components products consist of semiconductors, resistors, reactors, radiators, sensors, power capacitors, and heatsinks. Its energy and industrial products comprise marine engineering, electric vehicle, and inverter and converter systems, as well as provides railway maintenance and construction machines. The company was formerly known as Zhuzhou CSR Times Electric Co., Ltd. and changed its name to Zhuzhou CRRC Times Electric Co., Ltd. in March 2016. The company was incorporated in 2005 and is based in Wanchai, Hong Kong. Zhuzhou CRRC Times Electric Co., Ltd. is a subsidiary of CRRC Zhuzhou Institute Co., Ltd.
Full ZHUZY Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.